etrolizumab
roche
['ibd']
there were no significant differences between etrolizumab and placebo for the co-primary endpoints in the induction phase; by contrast, there were significant differences in the maintenance phase. vermeire notes high placebo rates in the induction phase #uegweek #gitwitter #ibd 
The Lancet Gastroenterology & Hepatology publishes high-quality peer-reviewed research and reviews, comment, and news #gastroenterology #hepatology. IF=45.042